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Abstract. This review covers recent developments in the inhibition of translocase MraY and 
related phospho-GlcNAc transferases WecA and TagO, and insight into the inhibition and 
catalytic mechanism of this class of integral membrane proteins from the structure of Aquifex 
aeolicus MraY. Recent studies have also identified a protein-protein interaction site in E. coli 
MraY, that is targeted by bacteriophage X174 lysis protein E, and also by cationic 
antimicrobial peptides containing Arg-Trp close to their N- or C-termini. 
 
 Bacteria contain several cell surface polysaccharides, of which the peptidoglycan cell 
wall is found in all eubacteria and is essential for maintenance of cell shape and protection 
against internal osmotic stress. Assembly of the polysaccharide on the cell surface requires an 
activated carbohydrate substrate that is able to cross the lipid bilayer of the cytoplasmic 
membrane. For this purpose, a C55 undecaprenyl lipid carrier is used in peptidoglycan 
biosynthesis, and is also used for other cell surface polymer biosynthetic pathways such as 
lipopolysaccharide biosynthesis, capsular polysaccharide biosynthesis, and teichoic acid 
biosynthesis [1].  The first step of these lipid-linked cycles is catalysed by an integral 
membrane protein, which for peptidoglycan biosynthesis is translocase MraY, which is the 
target for several natural product antibiotics [2]. This review will describe recent progress in 
the understanding of the enzymology and structure of this class of enzyme, and its inhibition 
by natural product and synthetic inhibitors, and by a phage bacteriolytic protein. 
 
Enzymology of MraY and related phospho-sugar transferases 
 Translocase MraY catalyses the reversible phosphotransfer reaction between 
UDPMurNAc-L-Ala--D-Glu-m-DAP-D-Ala-D-Ala and undecaprenyl phosphate to give 
undecaprenyl-diphospho-MurNAc-L-Ala--D-Glu-m-DAP-D-Ala-D-Ala (known as lipid 
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intermediate I) and UMP, shown in Figure 1 [3]. It is known to be a 10 transmembrane helix 
integral membrane protein whose conserved amino acid residues are found on cytoplasmic 
protein loops [4]. The catalytic mechanism of the enzyme could either involve a one-step 
phosphotransfer reaction at the -phosphate of the UDPMurNAc-pentapeptide substrate, or a 
two-step mechanism involving attack by an active site nucleophile [3]. There is evidence in 
favour of the two-step mechanism from isotope exchange studies by Neuhaus and coworkers 
[5]. There are only three conserved nucleophilic residues in the MraY sequence, three aspartic 
acid residues Asp-115, Asp-116 and Asp-267 for E. coli MraY. Replacement of each of these 
residues by Asn gives inactive enzyme [6,7], indicating their essential function in catalysis, 
and it has been proposed that two Asp residues may be involved in binding of the Mg2+ 
cofactor, and the other may be a catalytic nucleophile [6]. 
 
 
Figure 1. Reaction catalysed by translocase MraY, figure adapted from reference 2. 
 
 The crystal structure for Aquifex aeolicus MraY was determined in 2013 by Chung et al. 
to 3.3 Å resolution [8]. The enzyme was crystallised as a dimer, with an inter-dimer interface 
involving helices 10 and 7 (see Figure 2A). Helix 9 is severely bent, and points out 15-20 Å 
into the cytoplasmic membrane. At the active site of the enzyme, the three catalytic aspartic 
acid residues are positioned in the centre of the active site, close to the Mg2+ cofactor, which is 
ligated to Asp-265 (see Figure 2B). Polar residues Glu-300 and Gln-307 point into the active 
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site from bent helix 9, and two histidine residues His-324 and His-325 on a large cytoplasmic 
loop also point into the active site [8].  
We have recently used GOLD molecular docking software to explore the possible 
binding of the UDPMurNAc-pentapeptide substrate to A. aeolicus MraY. In one low energy 
conformation, shown in Figure 2C, the substrate diphosphate is bound to the Mg2+ cofactor, 
which has been proposed as a likely role of the Mg2+ cofactor [6]. The Mg2+ cofactor also 
contacts the ribofuranose 3’-hydroxyl group and endocyclic oxygen, as well as Asp-265, and 
the -phosphate also interacts with Lys-121. In this structure, Asp-117 is positioned 5.2 Å 
from the -phosphate of the substrate, directly in line with His-324, 8.3 Å away on the other 
side of the active site, with a cavity in between, where undecaprenyl phosphate could bind. 
Although docked structures should be interpreted with caution in the absence of 
experimental data, the spatial alignment of these three groups is interesting, since enzyme-
catalysed phosphotransfer reactions are known to generally proceed with an in-line 
geometry, with stabilisation of diphosphates by Mg2+ and an additional Arg or Lys residue [9]. 
Hence this conformation would be consistent with a two-step mechanism in which Asp-117 
attacks the -phosphate to generate a phospho-enzyme intermediate, and His-324/His-325 
position the phosphate group of undecaprenyl phosphate to carry out a second in-line 
displacement.  
The binding of phosphate groups by nitrogen macrocycles and supramolecular 
receptors containing 2-6 nitrogen atom donors is certainly precedented [10], and there are 
literature examples of supramolecular phosphate receptors containing two methylated 
imidazolium groups that bind the H2PO4- monoanion, shown in Figure 3 [11,12]. Hence we 
suggest that His-324/His-325 may sequester the phosphate monoanion of undecaprenyl 
phosphate, and activate it for nucleophilic attack on the phospho-enzyme intermediate. 
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1. Figure 2. Structure of A. aeolicus translocase MraY. A. Protein dimer, with active site on 
bottom right, labelling helices 7, 9, and 10. B. Active site, with catalytic Asp-117, Asp-118, 
and Asp-265 in red, Mg2+ cofactor in magenta, His-324 and His-325 in dark blue, and Glu-
300 and Gln-307 in cyan. C. Structure of A. aeolicus MraY docked with UDPMurNAc-
pentapeptide, obtained using GOLD molecular docking software [69], after removal of Ni2+ 
from the active site. Images drawn using PYMOL software [70].  
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Figure 3. Examples of bis-imidazolium supramolecular receptors for H2PO4- monoanion, from 
references 11 and 12. 
 
The first step of enterobacterial common antigen and O-antigen lipopolysaccharide 
(LPS) biosynthesis in Gram-negative bacteria is catalysed by WecA, related in sequence to 
MraY and also an integral membrane protein [13]. The reaction catalysed by WecA is the 
reversible reaction of UDPGlcNAc with undecaprenyl phosphate to give undecaprenyl-
diphospho-GlcNAc and UMP. WecA also contains conserved aspartic acid residues that are 
important for catalysis: replacement of Asp-156 by Asn in E. coli WecA gives inactive enzyme, 
whereas replacement of Asp-90 or Asp-91 by Asn gives mutant enzymes with residual activity 
[13], though replacement of both residues gives inactive enzyme [14]. 
 The first step of teichoic acid biosynthesis in Gram-positive bacteria, which is the same 
biochemical reaction as that catalysed by WecA, is catalysed by a related integral membrane 
protein TagO [15]. Interest in teichoic acid biosynthetic enzymes as antibacterial targets has 
been enhanced by the discovery that teichoic acid biosynthetic genes are essential for S. 
aureus nasal colonisation [16]. Campbell et al have shown that inhibition of TarO with 
tunicamycin  sensitises methicillin-resistant S. aureus strains to beta-lactam antibiotics, 
implying a fundamental connection between teichoic acid biosynthesis and peptidoglycan 
assembly in S. aureus [17]. Other homologues in this phospho-sugar transferase family 
include a glucose-1-phosphate transferase WcaJ involved in colonic acid capsule biosynthesis 
in E. coli and C. crescentus [18], and transferase WcfS involved in B. fragilis capsular 
polysaccharide biosynthesis [19].  
A further group of smaller 20-25 kDa phospho-sugar transferase enzymes containing a 
single transmembrane helix has also emerged, typified by C. jejuni PglC, which utilises a UDP-
di-N-acetyl-bacillosamine substrate, involved in N-glycoconjugate biosynthesis [20]. The 
function of conserved amino acid residues in this family of enzymes has recently been 
investigated using site-directed mutagenesis [21]. The properties of the different phospho-
sugar transferases mentioned here are summarised in Table 1 
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Table 1. Biochemical properties of phospho-sugar transferases 
 
 
Nucleoside natural product inhibitors of MraY and related enzymes 
Translocase MraY is the site of action for several nucleoside natural product 
antibiotics, including the mureidomycin/pacidamycin group of uridylpeptide antibiotics, the 
liposidomycin/caprazamycin group of liponucleoside antibiotics, and the muraymycin group 
of uridyldisaccharide antibiotics, which have been previously reviewed [2].  In recent years 
several studies have used synthetic chemistry to access analogues with higher chemical 
stability or altered antibacterial spectrum.  
In the muraymycin series (see structures in Figure 4), Tanino et al have demonstrated 
that the esterified hydroxyleucine residue can be replaced by a long chain alkyl sidechain, 
giving synthetic analogues with good in vitro MraY inhibition activity (IC50 0.33 µM, compared 
with muraymycin D2 IC50 0.01 µM) and antibacterial activity [22], and that the cyclic 
epicapreomycidine amino acid could be replaced by arginine, lysine or ornithine residues 
[23]. Using L-arginine in place of epicapreomycidine, Takeoka have further shown that the C-
terminal amino acid can be removed while retaining full MraY inhibition activity, and 
enhanced antimicrobial activity against strains of Pseudomonas, and that an analogue 
containing two L-arginine residues shows MIC 4-8 µg/ml against Pseudomonas strains [24]. 
Spork et al have synthesised a muraymycin analogue lacking the aminoribose sugar, which 
also retains MraY inhibition activity (IC50 2 µM) [25]. Ries et al have further shown that the -
guanylated fatty acid substituent found in the most active muraymycins is important for 
localisation of the antibiotic into the cytoplasmic membrane of the target organism [26]. 
These SAR data will help to inform the design of new analogues with improved antibacterial 
spectrum and pharmacokinetic properties.  
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Figure 4. Recent structure-activity studies on muraymycin natural product antibiotics 
 
In the caprazamycin series (see structures in Figure 5), an important discovery is that 
CPZEN-45, a semisynthetic caprazamycin derivative undergoing clinical trials for treatment of 
tuberculosis, preferentially targets transferase WecA in M. tuberculosis, rather than MraY [27]. 
CPZEN-45 retained activity against a strain of B. subtilis in which mraY was overexpressed, 
but lost activity against a strain in which transferase TagO was overexpressed, and was 8-fold 
more active in vitro against B. subtilis TagO (IC50 50 ng/mL) than MraY (IC50 400 ng/mL). In M. 
tuberculosis the homologue WecA is used in the biosynthesis of cell wall mycolyl 
arabinogalactan, and CPZEN-45 was found to inhibit M. tuberculosis WecA (IC50 40 ng/mL) 
>20 fold more strongly than caprazamycin G [27]. In contrast, the muraymycin analogues 
noted above were highly selective for MraY inhibition over E. coli WecA [23]. The action of 
CPZEN-45 will prompt further interest in the selective inhibition of WecA and TagO. Farha et 
al have shown that TarO is inhibited by anti-platelet drug ticlopidine [28], and the same 
authors have synthesised a set of ticlopidine analogues as TarO inhibitors [29]. 
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Ichikawa et al have synthesised analogues of caprazamycin in which the glutarate 
diester sidechain is replaced by a more stable alkyl chain, which retain strong biological 
activity [30]. Fer et al have also synthesised a series of triazole-containing analogues of the 
caprazamycins, which show IC50 values of 100-1000 µM against B. subtilis MraY, and show 
antibacterial activity against Staphylococcus aureus [31]. 
 
Figure 5. Recent structure-activity studies on the caprazamycin natural product antibiotics. R1 
= fatty acid sidechain; R2 = variable alkyl/aryl group. 
 
In the pacidamycin series (see structures in Figure 6), Okamoto et al have completed a 
total synthesis of pacidamycin D [32], and have used the synthetic route to investigate 
structure-activity relationships in he N-terminal dipeptide chain [33], shown previously to be 
important for biological activity in the mureidomycin series [34]. The stereochemistry of the 
2,3-diaminobutyric acid unit at C-2 was found to be important for both MraY inhibition and 
antibacterial activity, and meta-tyrosine was 180-fold more active for MraY inhibition than L-
tyrosine in the N-terminal dipeptide [33]. Two new series of peptidyl-uridines whose 
structures are based upon mureidomycin A and tunicamycin have been synthesised as 
inhibitors of C. jejuni PglC, and selected compounds show IC50 values in the range 40-250 µM 
[35]. The biosynthetic pathway to both the pacidamycin [36-38] and caprazamycin [39] 
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antibiotics has been elucidated, hence the use of biosynthetic engineering offers the 
possibility of generating modified uridyl peptide antibiotics via fermentation in the future. 
 
Figure 6. Recent structure-activity studies on the pacidamycin natural product antibiotics 
 
The enzyme-bound conformation of MraY nucleoside natural pduct inhibitors is still 
uncertain. The presence of a uridine nucleoside moiety also found in the UDPMurNAc-
pentapeptide substrate suggests that the uridine group probably binds in the same site in 
both substrate and inhibitor complexes. Kinetic studies of the inhibition of E. coli MraY has 
shown that mureidomycin A and liposidomycin B are both slow-binding inhibitors, while 
tunicamycin is a reversible inhibitor [40,41]. Inhibition by mureidomycin A was found to be 
competitive with both UDPMurNAc-pentapeptide and undecaprenyl phosphate substrates, 
whereas liposidomycin B was competitive with undecaprenyl phosphate, but non-competitive 
with UDPMurNAc-pentapeptide [41].  
 
Other classes of MraY inhibitors 
Using a fluorescence-based assay, the National Cancer Institute Diversity Set (~2000 
compounds) has recently been screened for inhibitors of E. coli MraY, which has led to the 
identification of one further natural product inhibitor, michellamine B (IC50 456 µM, see 
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Figure 7), a plant naphthylloquinone alkaloid [42]. Docking studies against the A. aeolicus 
MraY structure suggests that this structure binds to a hydrophobic cleft in the protein 
structure, rather than to the enzyme active site [42]. The inhibition of MraY by chlorinated 
fluoresceins, identified by a previous MraY/MurG screen by Bristol-Myers Squibb [43], was 
also investigated, and phloxine B was identified as an MraY inhibitor (IC50 32 µM, see Figure 
7), which is known to possess antibacterial activity [44]. Analogues of UDPMurNAc in which 
the diphosphate linkage was replaced by a -ketophosphonate linkage have also been 
synthesised, but no inhibition against B. subtilis MraY was observed for two uridine-
containing analogues, while lipid-linked analogues showed IC50 0.85-1.3 mM [45]. 
 
Figure 7. Structures of other MraY inhibitors 
 
Interaction of  MraY with bacteriophage X174 lysis protein E 
 In 2000, Bernhardt et al established using genetic methods that E. coli MraY is the site 
of action of the bacteriolytic lysis protein E of bacteriophage X174, a 91-amino acid protein 
that causes cell lysis of the host E. coli after phage particle assembly during the bacteriophage 
life cycle [46]. A host peptidyl-prolyl isomerase SlyD is also required for cell lysis, but variants 
of E (Epos) containing mutations R3H or L19F were isolated that do not require the slyD gene 
for cell lysis, and for these variants, the point mutation F288L in the mraY gene was found to 
cause resistance to E [46]. Mendel et al found that a synthetic peptide Epep containing the N-
terminal 37 amino acid transmembrane helix of E inhibits particulate MraY (IC50 0.8 µM), but 
not detergent-solubilised MraY, and they proposed that E inhibits MraY via a site distant from 
the active site, likely to be a protein-protein interaction site between MraY and other cell 
division proteins [47].  
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 A specific hypothesis for this protein-protein interaction site was recently proposed 
and investigated by Rodolis et al [48]. Construction of a helical wheel model for the 
transmembrane domain of E, and for helix 9 of MraY, resulted in the model shown in Figure 
8A. In the model, Phe-288 of MraY that is implicated in the E-MraY interaction from genetic 
studies [46] is positioned close to the indole sidechains of Trp-4 and Trp-7 of E, which could 
form favourable - stacking interactions with Phe-288 [48]. Also, the guanidine sidechain of 
Arg-3 of E could form an electrostatic interaction with neighbouring Glu-287 of MraY, which is 
conserved in bacterial MraY sequences.  
Rodolis et al found that synthetic pentapeptides mimicking this RWxxW motif 
inhibited particulate MraY (IC50 210-590 µM), but showed no inhibition of F288L or E287A 
site-directed mutants of MraY, thereby verifying a specific interaction with these amino acid 
residues [48]. One synthetic dipeptide Arg-Trp-octyl ester was found to show antimicrobial 
activity against E. coli (MIC 31 µg/mL), P. aeruginosa (MIC 40 µg/mL), and S. aureus (MIC 30 
µg/mL), and overexpression of the mraY gene in E. coli was found to raise the MIC value to 
250 µg/mL, implying that this is the site of antibacterial action [48]. Hence there appears to 
be a novel protein-protein interaction site in MraY, positioned on the outer face of the 
cytoplasmic membrane, which could be targeted by small molecule agents. The identity of the 
cellular protein-protein interaction partner for MraY is not known, and studies via yeast two-
hybrid technology are hindered by the reluctance of E. coli MraY to tolerate N- or C-terminal 
fusion tags, but there is evidence that MraY interacts with glycosyltransferase MurG, the next 
enzyme on the lipid cycle of peptidoglycan biosynthesis, and this interaction might mediate 
other interactions with a cell division complex [49]. 
Rodolis et al also observed that the structures of the nucleoside natural product MraY 
inhibitors contained elements of this RWxxW motif: muraymycin contains a 
epicapreomycidine analogue of arginine; while the pacidamycins contain a tryptophan at the 
C-terminus of the pentapeptide backbone, and a meta-tyrosine residue at the N-terminus [50]. 
They found that pacidamycin 1 showed 10-fold reduced inhibition against the F288L MraY 
mutant enzyme, implying some interaction of the antibiotic at this site, distant from the MraY 
active site [50]. Their rationalisation is that in order to access the MraY active site in vivo, they 
must first bind to the protein-protein interaction site, which leads to uptake of the inhibitor, 
probably via a protein conformational change, as shown in Figure 8B [50]. These observations 
might explain why simpler small molecule analogues of the nucleoside natural products that 
retain in vitro MraY activity often lose antibacterial potency, and why in general there is not a 
strong correlation between in vitro MraY inhibitory activity and antibacterial activity [3]. 
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Figure 8. A. Interaction site between MraY and bacteriolytic protein E from bacteriophage 
X174, showing RWxxW motif. B. Elements of RWxxW motif present in pacidamycin 
structure, rationalisation of the role of different structural elements (adapted from reference 
50). 
 
A novel site of action for cationic antimicrobial peptides containing Arg-Trp 
Interestingly, the RWxxW motif found in the lysis protein E is also observed close to 
the N- or C-terminus of several naturally occurring cationic antimicrobial peptides, including 
indolicidin [51], cecropin [52], tritrpticin [53], lactoferricin B [54], and puroindoline A [55] as 
shown in Table 2.  Many synthetic variants of cationic antimicrobial peptides have been 
generated by Hancock and co-workers, who have observed that Arg and Trp predominate in 
high activity peptide sequences [56-58], including that of clinical candidate MX226 
(Omiganan) [57]. Other short synthetic peptides containing Arg-Trp have also been reported 
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to show high levels of antimicrobial activity [59,60], even dipeptide derivatives based upon 
Trp-Arg [61]. 
 
Table 2. Cationic antimicrobial peptides containing Arg-Trp  
 
Several cationic antimicrobial peptides containing the RWxxW motif were found to 
show 30-60% inhibition of particulate E. coli MraY at 100 µg/mL concentration, indicating 
that these antibacterial peptides can target this site. Overexpression of the mraY gene in E. coli 
was found unusually to reduce the MIC value of some cationic antimicrobial peptides, the 
rationalisation being that the interaction with MraY may promote the insertion of the 
antibacterial peptides into the cytoplasmic membrane [48]. Hence it appears that this 
sequence motif is used by some cationic antimicrobial peptides in order to assist uptake into 
bacterial cells. Studies over many years on antimicrobial peptides has indicated that there are 
multiple sites of action for these compounds, due to the low incidence of resistance via genetic 
mutation [62], hence this appears to be a new site of interaction on the cell surface for 
antimicrobial peptides. Wenzel et al have also recently reported that treatment of B. subtilis 
with hexapeptide RWRWRW causes effects on cell wall biosynthesis, and the release of 
extrinsic membrane protein MurG from the cytoplasmic membrane [63]. Since MurG is known 
to interact with MraY [49], this effect might be caused by an initial binding to MraY, displacing 
MurG. 
 There is a question of whether this interaction site would only be an antibacterial 
target for E. coli, since Phe-288 is only conserved in MraY sequences from Enterobacteriaceae, 
and is replaced by Ile in Pseudomonas aeruginosa [48]. However, interestingly, the RWoct 
dipeptide derivative has antimicrobial activity against E. coli and P. aeruginosa [48]. In the 
crystal structure of A. aeolicus MraY [8], close to Phe-288 there are three other Phe residues 
forming a hydrophobic pocket, that may assist in the protein-protein interaction site, that are 
conserved in other Gram-negative MraY sequences. We note in Table 2 that many of the 
antibacterial peptides containing Arg-Trp sequences show activity against P. aeruginosa as 
well as E. coli. 
 Some protein E sequences found in other G4-like microviridae bacteriophages contain 
a Glu-His-Trp sequence in place of Arg-Trp, and a synthetic EHWGGG peptide was found to 
inhibit E. coli particulate MraY [48]. There are two reports of synthetically modified Trp-His 
and His-Arg dipeptides that show antimicrobial activity, although only weak activity against E. 
coli and P. aeruginosa, that might be connected with this observation [64,65]. 
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Summary and prospects 
 The continued emergence of new antibiotic-resistant bacterial pathogens with limited 
therapies underlines the need to identify novel targets for antibacterial action, and bacterial 
peptidoglycan biosynthesis remains a well-proven target for antibacterial action [66]. There 
has been increased research interest in the MraY family of phospho-sugar transferase 
enzymes in recent years, due to: the existence of several classes of nucleotide natural product 
antibiotics that target MraY [2]; the discovery that anti-TB drug candidate CPZEN-45 inhibits 
M. tuberculosis WecA rather than MraY [27]; and the existence of related phospho-sugar 
transferases involved in lipid-linked polysaccharide and glycoprotein biosynthesis pathways, 
for which selective inhibitors would be of great interest. The structure determination of A. 
aeolicus MraY [8] opens up possibilities for structure-based drug design against MraY and 
related enzymes. Although protein biochemistry for this group of integral membrane proteins 
remains very challenging, Bernard and co-workers have shown that recombinant MraY 
enzymes can be produced in good yield via cell-free protein expression [64], and can be 
reconstituted in nanodisc synthetic bilayers [68], offering an alternative to conventional 
protein expression technology. The discovery that Nature has also targeted MraY via a 
bacteriolytic lysis protein E and via antimicrobial peptides of diverse origins [48] suggests 
that it may be a relatively “weak spot” for antibacterial action that could ultimately yield new 
antimicrobial agents, in spite of the inherent practical difficulties. 
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Table 1. Properties and inhibitors of bacterial phospho-sugar transferases 
 
Enzyme Organism Nucleotide-sugar substrate 
[Pathway] 
Active site 
residues 
Inhibitors 
MraY  
 
 
 
 
 
 
WecA 
 
 
 
TagO 
 
 
WcaJ
  
 
 
WcfS 
 
 
 
 
PglC 
E. coli 
B. subtilis  
A. aeolicus  
 
 
 
 
E. coli  
M. tuberculosis 
 
 
Gram-positive 
Bacteria 
 
E. coli  
 
 
 
B. fragilis  
 
 
 
 
C. jejuni 
UDPMurNAc-pentapeptide 
[peptidoglycan biosynthesis] 
 
 
 
 
 
UDPGlcNAc 
[lipopolysaccharide 
biosynthesis]  
 
UDPGlcNAc 
[teichoic acid biosynthesis]  
 
UDP-Glucose 
[colonic acid capsule 
biosynthesis] 
 
UDP-acetamido-4-amino-6-
deoxy-galactose 
[Capsular polysaccharide 
biosynthesis] 
 
UDP-di-N-acetyl-
bacillosamine 
[N-glycoconjugate 
biosynthesis] 
 
Asp-115 
Asp-116 
Asp-267  
 
 
 
 
Asp-90 
Asp-91  
Asp-156 
Tunicamycin  
Mureidomycins/pacidamycins 
Liposidomycins/caprazamycins 
Muraymycins 
Capuramycins 
X174 E protein 
 
Tunicamycin  
CPZEN-45  
 
 
Tunicamycin 
Ticlopidine 
 
 
 
 
 
 
 
 
 
 
Peptidyl-uridine analogues 
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Table 2. Cationic antimicrobial peptides containing sequences related to the Arg-Trp-x-x-Trp sequence motif 
(highlighted in bold). Peptide sequences reported from N-terminus except where indicated. N, N-terminus; C, C-
terminus; NR, not reported. 
 
Peptide Sequence MIC values (µg/ml) MraY inhibition 
IC50 (µM) 
Ref 
E. coli P. aeruginosa 
X174 E pept i de 
I ndol i c i di n 
  Kai 47 
  Kai 50 
  MX226 
  Sub6 
  1002 
  Bac8c  
cecr opi n 
t r i t r pt i c i n 
l ac t of er r i c i n B 
pur oi ndol i ne A 
Shor t  Ar g- Tr p 
pept i des  
RWxxW mi mi cs  
 
 
 
 
 
 
 
  MVRWTLWDTLAFLLL 
 C- RRWPWWPWKWPLI  
 C- KRWKWWRFKWKI F 
 C- RRWWRWWRWKWRLI  
C- KRRWPWWPWRLI  
  C- RWWKI WVI RWWR 
N- VQRWLI VWRI RK 
 N- RRWI VWI R 
    KWKLFKKI EK 
  VRRFPWWWPFLRR 
EKCRRWQWRMKKLG 
   GKWWKWWRWTVPF 
 AcRRWWCF 
    RWRWRWRW 
    RWGLW 
    RWGGW 
    GWGLW 
    RGGLW 
    RWGLG 
    GWoct  
    RWoct  
l y t i c  
12. 5- 25 
31 
31 
38 
4- 16 
8 
2 
1. 0 
20 
24 
7 µM 
20 
10 µM 
-  
-  
-  
-  
-  
-  
31 
 
-  
2- 16 
NR 
NR 
19- 76 
31 
NR 
8 
5- 6 
1- 8 
NR 
NR 
45 
NR 
-  
-  
-  
-  
-  
-  
40 
 
0. 8  
90 
50 
40 
50 
40 
75 
 
 
 
 
 
 
 
590 
233 
209 
210 
274 
790 
>1000 
 
[ 47]  
[ 51]  
[ 58]  
[ 58]  
[ 57]  
[ 56]  
[ 48]  
[ 56]  
[ 52]  
[ 53]  
[ 54]  
[ 55]  
[ 59]  
[ 60]  
[ 48]  
[ 48]  
[ 48]  
[ 48]  
[ 48]  
[ 48]  
[ 48]  
 
      
 
     
      
 
          
      
 
